{"entity":{"id":"paper-a3961-intermediate-risk-neuroblastoma-baker-nejm-2010","kind":"paper","name":"A3961: outcome after reduced chemotherapy for intermediate-risk neuroblastoma","aka":[],"tldr":"Cutting chemotherapy to four or eight cycles based on tumour biology kept three-year survival above 96 percent in intermediate-risk neuroblastoma, showing these children could be safely treated with substantially less.","summary":"Children's Oncology Group prospective study of 479 children with intermediate-risk neuroblastoma treated with four cycles (favourable biology) or eight cycles (unfavourable biology) of carboplatin, etoposide, cyclophosphamide and doxorubicin, with surgery and no radiotherapy for most.\n\nThree-year event-free survival was 88 percent and overall survival 96 percent, similar to historical results with more intensive therapy, with excellent outcomes in the favourable biology group (96 percent overall survival).","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2010","url":"https://doi.org/10.1056/NEJMoa1001527"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/20879880/"}],"tags":[],"related":[],"cancers":["neuroblastoma-intermediate-risk"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2010,"doi":"10.1056/NEJMoa1001527","pmid":"20879880","authors":"Baker DL, Schmidt ML, Cohn SL, et al.","paperType":"observational","findings":["Three-year overall survival 96 percent; event-free survival 88 percent.","Four cycles sufficient for favourable biology."],"whatItMeans":"Biology-based reduction of chemotherapy is the standard for intermediate-risk neuroblastoma, and the successor trial ANBL0531 reduced it further.","caveats":["Non-randomised comparison with historical controls."],"changedPractice":true,"participants":479},"route":"/key-papers/paper-a3961-intermediate-risk-neuroblastoma-baker-nejm-2010/","neighbours":{"cancer":[{"id":"neuroblastoma-intermediate-risk","kind":"cancer","name":"Intermediate-risk neuroblastoma","route":"/cancers/neuroblastoma-intermediate-risk/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}